S-1: Palatin Technologies Launches Public Offering Amid Delisting Concerns

Palatin Technologies, Inc. announced a public offering of common stock and warrants to raise capital, while facing significant financial challenges and NYSE American delisting proceedings.

Summary

• Palatin Technologies, Inc. is offering up to 1,492,537 shares of Common Stock, along with Series J and Series K Common Warrants to purchase an equal number of shares.
• Pre-Funded Warrants are also offered as an alternative to Common Stock for purchasers whose beneficial ownership would exceed 4.99% (or 9.99%).
• The assumed combined public offering price is $10.05 per share of Common Stock and accompanying Common Warrants, and $10.0499 for Pre-Funded Warrants and accompanying Common Warrants.
• The offering includes a 7.0% underwriting discount and the issuance of Underwriter Warrants for 2.0% of the aggregate securities sold.
• Net proceeds from the offering are estimated at approximately $13.9 million, primarily for working capital and development of MC4R agonists for obesity.
• The company reported a net loss of $17.3 million for the year ended June 30, 2025, and an accumulated deficit of $459.1 million.
• As of June 30, 2025, cash and cash equivalents were $2.6 million, with current liabilities of $8.0 million, leading to substantial doubt about the company's ability to continue as a going concern.
• Palatin's Common Stock was suspended from trading on the NYSE American on May 7, 2025, and currently trades on the OTCQB Market under the symbol PTNT, with delisting proceedings affirmed by the NYSE American Listing Qualifications Panel.
• A 1-for-50 reverse stock split took effect on August 12, 2025.
• The company is engaged in litigation with H.C. Wainwright & Co., LLC for breach of contract, seeking monetary damages and warrants.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, including substantial net losses, a significant accumulated deficit, and a 'going concern' warning. The delisting from NYSE American and ongoing litigation are major negative indicators. While there are positive clinical trial results and a new collaboration, these are overshadowed by the immediate and critical financial and operational challenges, making the investment highly speculative and risky.

Positives

• Successful Phase 2 clinical study for obesity with co-administration of bremelanotide and tirzepatide demonstrated increased weight loss over tirzepatide alone.
• PL8177 (ulcerative colitis) Phase 2 clinical trials showed one-third of patients achieved clinical remission, with no clinical remission in the placebo group.
• An MC4 agonist for diabetic nephropathy reported positive topline data in the fourth quarter of 2024.
• PL9643 (ophthalmic peptide solution for dry eye disease) completed a first Phase 3 clinical trial with positive topline results in Q1 2024 and had a positive Type C meeting with the FDA.
• Entered a global research collaboration and licensing agreement with Boehringer Ingelheim for retinal diseases, including an upfront payment of €2.0 million ($2.3 million USD) and potential milestone payments up to €260 million ($307.0 million USD) plus tiered royalties.
• The company's Vyleesi product was acquired by Cosette Pharmaceuticals, Inc. in December 2023, with potential for future milestone payments based on sales.
• Management (CEO, CFO/COO, and certain directors) have indicated interest in participating in this offering at the public offering price and on the same terms as other purchasers.

Negatives

• Reported a substantial net loss of $17.3 million for the year ended June 30, 2025, and an accumulated deficit of $459.1 million.
• Cash and cash equivalents of $2.6 million against current liabilities of $8.0 million as of June 30, 2025, raise substantial doubt about the ability to continue as a going concern.
• The Common Stock was suspended from trading on the NYSE American on May 7, 2025, and delisting proceedings have been affirmed.
• The company is currently trading on the OTCQB Market, which may result in reduced liquidity, limited market quotations, and a 'penny stock' designation.
• Immediate and substantial dilution of $6.24 per share for new investors participating in this offering.
• Uncertainty regarding the receipt of significant milestone payments from Vyleesi sales or the Boehringer Ingelheim agreement for the next 12 to 24 months.
• Ongoing litigation with H.C. Wainwright & Co., LLC for breach of contract, seeking monetary damages and warrants.

Risks

• Substantial net losses are expected for the foreseeable future, and profitability may never be achieved or maintained.
• Additional funding is required to complete clinical trials and development activities, which may not be available on acceptable terms or at all.
• Insufficient funding could lead to significant curtailment of operations, cessation of clinical trials, and decreased staffing levels.
• Changes in funding for regulatory agencies (FDA, SEC) could hinder product development or commercialization.
• The delisting from NYSE American could lead to limited market quotations, reduced liquidity, 'penny stock' designation, limited news/analyst coverage, and decreased ability to raise future financing.
• New investors will experience immediate and substantial dilution of $6.24 per share.
• Management has broad discretion over the use of offering proceeds, which may not be applied effectively.
• Future sales of common stock or the perception of such sales may depress the stock price.
• The stock price may fluctuate significantly due to various factors unrelated to company performance.
• No cash dividends are anticipated in the foreseeable future; capital appreciation is the sole source of gains.
• There is no public trading market for the Common Warrants or Pre-Funded Warrants, limiting their liquidity and making them speculative.
• The company may not receive additional funds if warrants are exercised via cashless exercise.
• Provisions of the Common Warrants and Pre-Funded Warrants could discourage third-party acquisitions.
• Ongoing litigation with H.C. Wainwright & Co., LLC could result in significant monetary damages or warrant awards.

Future Outlook

The company expects to incur substantial net losses for the foreseeable future and may never achieve or maintain profitability. Future efforts will focus on bremelanotide combination products and MC1R product candidates, primarily for ocular indications. Investigational New Drug (IND) filings are projected for a novel once-weekly MC4R peptide agonist and PL7737 (oral small molecule MCRR agonist) in the first quarter of calendar year 2026. Patient enrollment for PL9643 (dry eye disease) could commence as early as the second half of calendar year 2025, depending on financial resources and product development priority.

Management Comments

• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for one year after the date of their consolidated financial statements issued on May 14, 2025.
• The company is actively seeking additional funding to complete development activities and required clinical trials for MCR product candidates and, if successful, to complete submission of required regulatory applications to the FDA.

Industry Context

Palatin Technologies operates in the biopharmaceutical sector, specializing in medicines that modulate melanocortin receptor systems (MCR) for various indications including inflammation, immune response, food intake, metabolism, and sexual function. The company is developing MC4R agonists for obesity and metabolic disorders, and MC1R agonists for inflammatory and autoimmune diseases like dry eye disease. The successful Phase 2 results for bremelanotide co-administration with tirzepatide for obesity positions Palatin within the competitive and rapidly evolving GLP-1 agonist market. The collaboration with Boehringer Ingelheim for retinal diseases highlights a strategic move into a specialized therapeutic area, leveraging its melanocortin receptor-targeted peptides.

Comparison to Industry Standards

• The Phase 2 clinical study for obesity with co-administration of bremelanotide with tirzepatide (a GLP-1 agonist) demonstrated an increased weight loss over tirzepatide alone, suggesting a potential synergistic effect compared to a known industry standard treatment for obesity.
• PL8177's Phase 2 results for ulcerative colitis, showing one-third of patients achieving clinical remission while the placebo group saw none, indicate a potentially favorable outcome compared to standard placebo responses in clinical trials for inflammatory bowel disease.

Corporate Governance

Legal Proceedings

• On February 13, 2025, H.C. Wainwright & Co., LLC filed a complaint against Palatin Technologies, Inc. in the Supreme Court of the State of New York, County of New York (Case No: 650878/2025).
• The complaint asserts three causes of action for breach of contract and seeks monetary damages and the award of warrants allegedly due under an engagement agreement dated January 29, 2024.
• On March 20, 2025, the company filed its answer, denying all liability and asserting several affirmative defenses, and plans to vigorously defend against the lawsuit.

Stakeholder Impact

• **Shareholders**: Will experience immediate and substantial dilution from the offering. Face risks of reduced liquidity and trading activity due to delisting from NYSE American. No cash dividends are anticipated in the foreseeable future. The value of warrants is speculative.
• **Employees**: Potential for decreased staffing levels if the company fails to secure sufficient additional funding to support operations and clinical trials.
• **Customers**: Continued product development, particularly for obesity, dry eye disease, and ulcerative colitis, could lead to new therapeutic options.
• **Creditors**: The 'going concern' warning and significant accumulated deficit indicate increased risk regarding the company's ability to meet its financial obligations.
• **Underwriters (A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd.)**: Will receive a 7.0% cash fee and warrants for 2.0% of the aggregate securities sold in the offering. They also have an over-allotment option for additional shares.

Next Steps

• The company will continue to seek additional funding to complete development activities and required clinical trials for MCR product candidates.
• If clinical trials are successful, the company plans to complete submission of required regulatory applications to the FDA.
• The appeal regarding the NYSE American delisting decision will be heard by the full Committee for Review on September 30, 2025.
• PL9643 (dry eye disease) can commence patient enrollment as early as the second half of calendar year 2025, depending on financial resources and product development priority.
• IND filing projected in the first quarter of calendar year 2026 for a novel once-weekly melanocortin receptor-4 (MC4R) peptide agonist for obesity indications.
• IND filing projected in the first quarter of calendar year 2026 for PL7737, an oral small molecule MCRR agonist.
• The litigation with H.C. Wainwright & Co., LLC will proceed to the discovery stage and for further proceedings.

Key Dates

Recommendation

Palatin Technologies is in a precarious financial position, evidenced by substantial net losses, a large accumulated deficit, and a 'going concern' warning from its auditors. The delisting from NYSE American and subsequent trading on the OTCQB significantly reduce market visibility and liquidity, increasing investment risk. While the company has promising clinical pipeline developments and a new collaboration, these long-term prospects are overshadowed by immediate financial instability and the need for continuous capital raises, which will lead to further shareholder dilution. The ongoing litigation adds another layer of uncertainty. Given the severe financial and operational risks, a seasoned investor would likely recommend a 'strong sell' to mitigate potential further losses.

Keywords

Biopharmaceutical, Melanocortin Receptor, Obesity Treatment, Dry Eye Disease, Ulcerative Colitis, Diabetic Nephropathy, SEC Filing, Public Offering, Common Stock, Warrants, Delisting, Going Concern, Clinical Trials, Drug Development, Biotech Investment